SINOHEALTH TECH (Sinohealth Technology Holdings Limited) reported 1H26 revenue of RMB161.51 million, a 9.2% year-on-year increase driven by AI-related growth and steady performance in core commercial solutions.

• Segment mix – Commercial Solutions rose 9.9% to RMB126.61 million; Data Insight Solutions within the segment added 11.5% to RMB94.55 million, while DaaS and other solutions fell 41.9% after AI-enabled products were reclassified. – AI Applications revenue surged 295.0% to RMB16.85 million, reflecting the first commercial contributions from agents such as GHIC, MedMate and upgraded CHIS. – Data-driven Publications & Events edged up 1.6% to RMB33.24 million.

• Profitability Gross profit improved 10.0% to RMB90.33 million with margin up 0.4 ppt to 55.9%. Operating profit fell 46.6% to RMB8.67 million, and net profit plunged 86.1% to RMB3.40 million, pushing net margin down to 2.1% (1H25: 16.6%). Management attributed the earnings decline to: 1) a 17.3% jump in R&D spending to RMB38.75 million as the company expanded AI capabilities; 2) higher selling expenses (+22.1% to RMB21.44 million) linked to agent commercialisation; and 3) a RMB12.39 million foreign-exchange loss plus lower interest income following global rate cuts.

• Balance sheet & cash flow Total assets reached RMB846.21 million (+2.5% half-on-half), with equity at RMB728.61 million and liabilities at RMB117.59 million, giving a gearing ratio of 16.1%. Cash, time deposits and equivalents stood at RMB382.25 million, down from RMB639.92 million a year earlier as funds were redeployed into low-risk wealth-management products. The group remains debt-free aside from RMB5.75 million in lease liabilities.

• Operational highlights – AI medical big-data services doubled revenue to RMB9.6 million by expanding into innovative drug R&D, market-access and real-world evidence projects. – The GHIC commercial decision-making agent served over 70 pharma clients; SIC pharmacy platform covered 67,163 fully-operational stores. – R&D agent “Deep Pharma” debuted 1 July 2026, extending AI support to drug discovery and BD decisions.

• Dividend The board declared no interim dividend for 1H26. A final dividend of HK$0.0712 per share (RMB28 million) for FY25 was paid in June.

• Outlook Management reaffirmed its positioning as an “AI technology services company” and will prioritise scaling agent platforms across R&D decision-making, commercial growth, medical services and consumer health, while continuing to invest in the dual-model architecture—“Woodpecker” Medical Large Model and “Tiangong No.1” Decision-making Large Model.